LLY’s Retatrutide Delivers Significant Weight Loss and Pain Relief in Phase 3 Knee Osteoarthritis Trial
Triple Agonist Shows Up to 28.7% Body Weight Loss and 75.8% Reduction in Osteoarthritis Pain
Eli Lilly’s investigational drug retatrutide, a first-in-class triple hormone receptor agonist, achieved remarkable results in the Phase 3 TRIUMPH-4 trial for adults with obesity and knee osteoarthritis. Participants on the highest dose (12 mg) lost an average of 28.7% of their body weight—or about 71.2 pounds—over 68 weeks, alongside a 75.8% drop in knee pain as measured by the WOMAC pain score. More than 1 in 8 treated patients reported being completely free of knee pain at the end of the trial.
Key Data Highlights: Dose Response Outshines Placebo in Every Category
| Endpoint | Retatrutide 9 mg | Retatrutide 12 mg | Placebo |
|---|---|---|---|
| Body Weight Change (%) | -26.4% (-64.2 lbs) |
-28.7% (-71.2 lbs) |
-2.1% (-4.6 lbs) |
| WOMAC Pain Score Change | -4.5 points (-75.8%) |
-4.4 points (-74.3%) |
-2.4 points (-40.3%) |
| Achieved =25% Weight Loss | 47.7% | 58.6% | 1.3% |
| Achieved =30% Weight Loss | 30.5% | 39.4% | 0.8% |
| Achieved =35% Weight Loss | 18.2% | 23.7% | 0.0% |
| Physical Function Score Change | -4.1 points (-71.8%) |
-4.2 points (-73.7%) |
-2.1 points (-35.6%) |
| =70% Reduction in Pain | 73.0% | 67.7% | 26.2% |
More Than 12% of Treated Patients Became Completely Pain-Free
Beyond the headline numbers, the data point to a substantial clinical impact: in post-hoc analysis, 14.1% of those on the 9 mg dose and 12.0% on the 12 mg dose were completely free of knee pain after 68 weeks, compared with only 4.2% for the placebo group.
Retatrutide Shows Promise Beyond Weight Loss: Cardiometabolic Improvements Noted
The trial also found meaningful improvements in secondary endpoints such as reductions in non-HDL cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), and a decrease in systolic blood pressure by up to 14 mmHg at the highest dose. These cardiometabolic markers hint at broader potential health benefits for patients struggling with obesity and osteoarthritis.
Adverse Events in Line with Other Incretin Therapies
Common adverse events for retatrutide (nausea, diarrhea, constipation, vomiting, and decreased appetite) were consistent with similar drugs and dose-dependent. Importantly, most cases of dysesthesia (altered sensation) were mild and rarely resulted in treatment discontinuation. Overall discontinuation rates were comparable between drug and placebo groups, with slightly higher rates tied to higher baseline BMIs and some cases due to perceived excessive weight loss.
What’s Next? Seven Additional Phase 3 Trials to Conclude by 2026
Lilly’s ongoing TRIUMPH program includes seven more Phase 3 trials, evaluating retatrutide in broader indications like type 2 diabetes, sleep apnea, and cardiovascular outcomes. These results, expected in 2026, will help define retatrutide’s place in the growing market for obesity and metabolic disease therapies.
Takeaway: Retatrutide Sets a New Bar for Weight and Pain Reduction
The TRIUMPH-4 study sets retatrutide apart for patients facing obesity and osteoarthritis, showing potential to transform standards of care for those needing significant weight loss and pain management. Investors and clinicians will be watching for upcoming trial readouts and possible regulatory milestones that could further establish retatrutide as a leading option in this expanding field.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI